Len Post

Company: Vivace Therapeutics Inc

Job title: Chief Scientific Officer

Seminars:

Panel Discussion: An Overview of the Hippo Pathway Drug Development Landscape 9:00 am

What indications are showing most promise for therapeutic intervention on the Hippo pathway? Will targeted approaches on TEAD isoforms be the key to navigating risk of toxicity from pan-TEADs? How do we convince investors Hippo pathway treatments are worth their time when some consider the pathway ‘unvalidated’? What are the advantages/risks in targeting YAP/TAZ and…Read more

day: Conference Day One

Phase 1 trial of TEAD inhibitor VT3989 : Trial status and future directions 2:45 pm

Exploring Phase 1 clinical data of VT3989 Detailing translation of preclinical data to clinical results Reviewing tuture development directionsRead more

day: Conference Day One